Early cancer detection tests that focus solely on pancreatic cancer are also being investigated. Ruijin hospital is collaborating with Burning Rock Dx for an upcoming clinical trial that is recruiting over 7000 participants. The ASCEND-PANCREATIC muti-omics, observational study (NCT05556603) will aim to detect pancreatic cancer with combined assays of biomarkers for cfDNA methylation, circulating tumor DNA mutations, serum protein markers, and miRNA. Peking Union Medical College Hospital is also conducting an active clinical trial (NCT05689138) analyzing the gut and fecal microbiome of participants with and without pancreatic cancer to establish an early detection tool and discover diagnostic biomarkers. The Moffitt Cancer Center also researched early pancreatic diagnostics with a completed clinical trial (NCT02948946) evaluating a blood based multigene RNA transcript assay for gastroenteropancreatic neuroendocrine tumors among 100 cancer and healthy participants. The NETest was found to be highly sensitive (98%) and specific with 48 true positive results and one false negative. Lastly, early cancer detection tests focused solely on liver cancer are examined. Glycotest seeks to validate their Glycotest HCC panel for the early detection of hepatocellular carcinoma. Their large multicenter clinical trial (NCT03878550) will include patients with earlystage HCC against non-cirrhosis and cirrhotic patients without HCC. The main objective will determine if the Glycotest HCC panel will be superior to current alpha-fetoprotein surveillance techniques. Helio Genomics also researched their HelioLiver test in a completed clinical trial called the ENCORE study (NCT05059665 ). They found that HelioLiver showed superior performance to current AFP and GALAD (gender, age, AFP-L3, AFP, des-gamma-carboxy prothrombin) techniques. They are continuing their research with an active clinical trial (NCT03694600) to further explore HelioLiver's performance in detection of DNA methylation profiles of cell-free DNA whole blood specimens. Finally, Owlstone medical has researched their breathalyzer for breath biopsy testing of liver disease and hepatocellular carcinoma in a recently completed clinical trial NCT03756597. Their breath biopsy system measures Volatile Organic Compounds (VOCs) for disease surveillance. Endogenous VOCs are produced throughout the body and are distributed in the bloodstream, they exchange in the lungs and are exhaled. Exhaled VOCs contribute to biomarker discovery by affording a source of valuable biomarkers with distinct associations to the body metabolism. Results from this trial are encouraging, revealing 7 known and novel VOCs for a liver disease biomarker panel that can be utilized for disease detection. 215